1.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
by Noh, Sung Hoon, Prof
The lancet oncology, 2014, Vol.15 (12), p.1389-1396
2.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, p...
by Wang-Gillam, Andrea, MD
The Lancet (British edition), 2016, Vol.387 (10018), p.545-557
3.
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
by Suker, Mustafa, MD
The lancet oncology, 2016, Vol.17 (6), p.801-810
4.
Pancreatic cancer
by Kamisawa, Terumi, Dr
The Lancet (British edition), 2016, Vol.388 (10039), p.73-85
5.
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase...
by Neoptolemos, John P, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1011-1024
6.
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phas...
by Yang, James Chih-Hsin, Prof
The lancet oncology, 2015, Vol.16 (2), p.141-151
7.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
by Uesaka, Katsuhiko, MD
The Lancet (British edition), 2016, Vol.388 (10041), p.248-257
8.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
by Zhang, Li, Prof
The Lancet (British edition), 2016, Vol.388 (10054), p.1883-1892
9.
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
by Simkens, Lieke H J, MD
The Lancet (British edition), 2015, Vol.385 (9980), p.1843-1852
10.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
by Bang, Yung-Jue, Prof
The Lancet (British edition), 2012, Vol.379 (9813), p.315-321
11.
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
by Lordick, Florian, Prof
The lancet oncology, 2013, Vol.14 (6), p.490-499
12.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,...
by Sax, Paul E, Dr Prof
The Lancet (British edition), 2015, Vol.385 (9987), p.2606-2615
13.
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
by Fang, Wenfeng
The lancet oncology, 2018, Vol.19 (10), p.1338-1350
14.
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
by Cunningham, David, Prof
The lancet oncology, 2013, Vol.14 (11), p.1077-1085
15.
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids
by Huang, Ling
Nature medicine, 2015, Vol.21 (11), p.1364-1371
16.
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
by Jiang, Hong
Nature medicine, 2016, Vol.22 (8), p.851-860
17.
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
by Bachelot, Thomas, Dr
The lancet oncology, 2013, Vol.14 (1), p.64-71
18.
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised control...
by Seddon, Beatrice
The lancet oncology, 2017, Vol.18 (10), p.1397-1410
19.
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
by Primrose, John, Prof
The lancet oncology, 2014, Vol.15 (6), p.601-611
20.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,...
by Zhou, Caicun, Prof
The lancet oncology, 2011, Vol.12 (8), p.735-742
